Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Teerlink

Showing results (41-50 of 351) with videos related to

Pageof 36
Sort By:
Journal of the American College of Cardiology|February 4, 2012
Bile salts for the treatment of heart failure: out on a limb for a gut feeling?James M McCabe, John R Teerlink
Heart Failure Clinics|July 2, 2013
Strategies to prevent postdischarge adverse events among hospitalized patients with heart failureMitchell A Psotka, John R Teerlink
Expert Opinion on Drug Safety|January 7, 2017
The safety of sacubitril-valsartan for the treatment of chronic heart failureJeffrey M Tyler, John R Teerlink
Critical Care Medicine|February 19, 2008
Acute heart failure: emerging from the shadowsSteven M Hollenberg, John R Teerlink
Expert Review of Cardiovascular Therapy|May 31, 2008
Role of tolvaptan in acute decompensated heart failureJennifer E Ho, John R Teerlink
Nature Cardiovascular Research|December 5, 2024
New and future heart failure drugsLeila Haghighat, Colette DeJong, John R Teerlink
The American Journal of Cardiology|September 27, 2005
Pharmacology of new agents for acute heart failure syndromesMihai Gheorghiade, John R Teerlink, Alexandre Mebazaa
Journal of the American College of Cardiology|July 4, 2015
Reply: Mode of Death Prevention by SerelaxinG Michael Felker, Marco Metra, John R Teerlink
JACC. Heart Failure|February 5, 2025
Designing Effective Trials for Acute Decompensated Heart FailureJohannes Grand, Tor Biering-Sørensen, John R Teerlink
Pflugers Archiv : European Journal of Physiology|May 6, 2014
Novel drug mechanisms in development for heart failureSoidjon D Khodjaev, John R Teerlink, Fady I Malik
Pageof 36

Showing results (41-50 of 351) with videos related to

Sort By:
Pageof 36
Journal of the American College of Cardiology|February 4, 2012
Bile salts for the treatment of heart failure: out on a limb for a gut feeling?James M McCabe, John R Teerlink
Heart Failure Clinics|July 2, 2013
Strategies to prevent postdischarge adverse events among hospitalized patients with heart failureMitchell A Psotka, John R Teerlink
Expert Opinion on Drug Safety|January 7, 2017
The safety of sacubitril-valsartan for the treatment of chronic heart failureJeffrey M Tyler, John R Teerlink
Critical Care Medicine|February 19, 2008
Acute heart failure: emerging from the shadowsSteven M Hollenberg, John R Teerlink
Expert Review of Cardiovascular Therapy|May 31, 2008
Role of tolvaptan in acute decompensated heart failureJennifer E Ho, John R Teerlink
Nature Cardiovascular Research|December 5, 2024
New and future heart failure drugsLeila Haghighat, Colette DeJong, John R Teerlink
The American Journal of Cardiology|September 27, 2005
Pharmacology of new agents for acute heart failure syndromesMihai Gheorghiade, John R Teerlink, Alexandre Mebazaa
Journal of the American College of Cardiology|July 4, 2015
Reply: Mode of Death Prevention by SerelaxinG Michael Felker, Marco Metra, John R Teerlink
JACC. Heart Failure|February 5, 2025
Designing Effective Trials for Acute Decompensated Heart FailureJohannes Grand, Tor Biering-Sørensen, John R Teerlink
Pflugers Archiv : European Journal of Physiology|May 6, 2014
Novel drug mechanisms in development for heart failureSoidjon D Khodjaev, John R Teerlink, Fady I Malik
Pageof 36